The Ministry of Health and Family Welfare (Govt. of India) on January 18, 2022, has issued the Drugs (Amendment) Rules, 2022 to further amend the Drugs Rules, 1945.
The amendment makes QR codes mandatory on every active pharmaceutical ingredient. The Amendment Rules will come into force from January 01, 2023.
In Rule 96 Relating To The Manner Of Labelling, The Following Sub-rule Shall Be Inserted:
According to the gazette notification, the new drug amendments rule states that every active pharmaceutical ingredient (API) imported or manufactured in India shall bear a QR (quick response) code on the label and at every packaging level. The QR code must encase essential data that can be read through computer software for efficient tracking and tracing.
Special storage conditions required (if any). This amendment will come into force on the 1st of Jan 2023. You will need to implement a solution before that.
The Stored Data Must Contain the Following Information
- Unique product identification code
- Name of the API
- Brand name (if any)
- Name and address of the manufacturer
- Batch no.
- Batch size
- Date of manufacturing
- Date of expiry or retesting
- Serial shipping container code (SSCC)
- Manufacturing licence no. or import licence no.
Reference:
https://cdsco.gov.in/opencms/opencms/en/Notifications/Gazette-Notifications/
Stakeholders are being encouraged to weigh in on the European Chemicals Agency (ECHA) 60-day public consultation period related to a planned ban on per-and-polyfluoroalkyl (PFAS) substances, also known as forever chemicals.
We’re pleased to share an important milestone in our sustainability journey.
ExSyn has been awarded the EcoVadis Platinum Medal, placing us among the top 1% of companies globally evaluated for environmental, social and ethical performance.
While fears around a complete shutdown of the Strait of Hormuz primarily raise concerns around oil prices and energy security, recent history shows that even partial disruptions or security threats along key sea routes can quickly spill over into freight inflation, longer transit times and working capital stress for exporters and importers.
The European Union (EU) has agreed to offer Indian pharmaceutical and medical devices companies preferential access to EU market, along with cutting tariffs on 97.5 percent of chemical products to zero.
As we approach the close of this year, we at ExSyn would like to extend our heartfelt gratitude for your trust, collaboration, and continued support. Your confidence in our products and services has been the driving force behind our growth and success.
The U.S. Food and Drug Administration (FDA) today announced significant action to make it faster and less costly to develop biosimilar medicines, which are lower-cost “generic” alternatives to biologic drugs that treat serious and chronic diseases.
Products containing titanium dioxide in the EU are no longer required to carry warnings about cancer risk, after the European Chemicals Agency (Echa) revoked its classification as a suspected carcinogen. The move follows a June 2025 decision by the Court of Justice of the European Union and means that safety data sheets, labelling and packaging requirements for titanium dioxide have been relaxed across industries including paints, pharmaceuticals, cosmetics and food.
The economic impact of biosimilars on the Australian health care system is now clearer, with data revealing their role in reducing market expenditure and driving price competition.
The Chinese Golden Week impacts Ocean Freight Shippers for two main reasons: